Shields RK, et al. – This study sought to compare outcomes of patients treated with ceftazidime–avibactam versus comparators for carbapenem–resistant Enterobacteriaceae infections. Observations suggested ceftazidime–avibactam as superior to other treatment regimens against carbapenem–resistant Klebsiella pneumoniae bacteremia.

• Authors at their center identified higher rates of clinical success (P = 0.006) and survival (P = 0.01) with ceftazidime–avibactam treatment of carbapenem–resistant Klebsiella pneumoniae bacteremia in comparison to other regimens.
• Across treatment groups, they noticed no differences regarding underlying diseases, severity of illness, source of bacteremia, or strain characteristics (97% produced K. pneumoniae carbapenemase).
• Increased rates of nephrotoxicity were evident with aminoglycoside– and colistin–containing regimens (P = 0.002).